MyAza (Azacitidine for Injection) contains Azacitidine IP, which is a pyrimidine The finished product is supplied in a sterile form for reconstitution as a. No formal clinical drug interaction studies with azacitidine have been conducted. The printed package leaflet of the medicinal product must state the name. Drug: Azacitidine – Vidaza® Oncology – Intravenous Dilution Data. (, ) – [ SEE PACKAGE INSERT FOR ADDITIONAL DETAILS]].
|Published (Last):||26 January 2015|
|PDF File Size:||17.52 Mb|
|ePub File Size:||7.5 Mb|
|Price:||Free* [*Free Regsitration Required]|
Related Drug Information Drug Summary. Several guidelines on this subject have been published. Antimetabolites are very similar to normal substances within the cell.
The reconstituted product may be kept in the vial or drawn into a syringe. Am J Health-Syst Pharm. Reconstitute each vial with inert mL sterile water for injection. Preparation for Delayed Subcutaneous Administration: We do not record any personal information entered above.
Handling and Disposal Procedures for proper handling and disposal of anticancer drugs should be applied. Women who become pregnant while receiving azacitidine should be apprised of the potential hazard to the fetus. If it comes in contact with mucous membranes, flush thoroughly with water.
After removal from refrigerated conditions, the suspension may be allowed to equilibrate to room temperature for up to 30 minutes prior to administration. A dosage adjustment in subsequent cycles may be required based on nadir counts and hematologic response.
By this process of demethylation, normal function to the azacitivine suppressor genes is restored, thus restoring control over cell growth. Contact your health care provider within 24 hours of noticing any of the following: New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, red, or hard.
Dilute immediately by injecting the calculated amount of azacitidine into a 50 to mL infusion bag of either 0. Moderate Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of antineoplastic agents. Whether azacitidine metabolism may be affected by known microsomal enzyme inhibitors or inducers has not been studied.
Vidaza (azacitidine) dose, indications, adverse effects, interactions from
When suppressor genes are blocked, azaciitidine division becomes unregulated, allowing or promoting cancer. Azacitidine has been designated an orphan drug for this indication. Shake or roll the vial vigorously until all powder is dissolved; the solution should be clear. The product may be held at room temperature for up to 1 hour, but must be administered within 1 hour after reconstitution. Azacitidine inhibition of DNA methyltransferase is dose- and time-dependent.
Special Populations The effects of renal inseert hepatic impairment, gender, age, or race on the pharmacokinetics of azacitidine have not been studied [see Dosage and Inser 2. Published studies indicate that urinary excretion is the primary route of elimination of azacitidine and its metabolites.
Among those patients, overall survival was Females of reproductive potential should avoid pregnancy during treatment with azacitidine. Significant hematologic toxicity was noted with no response as defined by bone marrow remission or improvement in transfusion requirements.
Based on data in animals, infertility may occur in male or females treated with azacitidine.
Vigorously shake or roll the vial until all solids are dissolved. Azacitidine and its metabolites are primarily excreted by the kidney; therefore, use caution in geriatric patients or patients with renal impairment and closely monitor renal function. Instructions for Intravenous Administration.
Azacitidine – Drug Information – Chemocare
Pregnancy testing should be performed prior to starting azacitidine in female patients of reproductive potential. Because elderly patients ppackage more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Warnings and Precautions 5. Your Name Your name is required.
Azacitidine is contraindicated in patients with advanced hepatic malignancies. When the cells incorporate these substances into the cellular metabolism, they interact with a number of targets within the cell to produce a direct cytotoxic effect that causes death of rapidly dividing cancer cells.
Storage following reconstitution mannitol-containing formulations: Azacitidine has not been evaluated in patients with myelodysplastic syndrome and hepatic impairment; use is contraindicated in patients with advanced hepatic malignancy.
The information contained in this website is meant to be helpful and educational, but zzacitidine not a substitute for medical advice. Drug-Drug Interactions Drug interaction packag with azacitidine have not been conducted.